Literature DB >> 17989335

Mycobacterium bovis bacillus Calmette-Guerin induces CCL5 secretion via the Toll-like receptor 2-NF-kappaB and -Jun N-terminal kinase signaling pathways.

Patricia Méndez-Samperio1, Artemisa Trejo, Aline Pérez.   

Abstract

In response to Mycobacterium bovis bacillus Calmette-Guérin (BCG), CC chemokines are secreted from host cells to attract components of the innate and adaptive immune systems to the site of infection. Toll-like receptor 2 (TLR2) has been shown to recognize M. bovis BCG and to initiate signaling pathways that result in enhanced secretion of CC chemokines. Despite the essential requirement of TLR2 in M. bovis BCG infection, the mechanisms by which it induces secretion of CC chemokines are not well defined. In this study, we report that stimulation of HEK293 cells expressing human TLR2 with M. bovis BCG resulted in increased CCL2 and CCL5 secretion, as determined by an enzyme-linked immunosorbent assay. M. bovis BCG infection resulted in the activation of c-Jun N-terminal kinase (JNK), and the inhibition of JNK activity had a significant effect on M. bovis BCG-dependent CCL5 secretion in TLR2-expressing cells but no effect on M. bovis BCG-dependent CCL2 secretion from infected HEK293 cells expressing human TLR2. The M. bovis BCG-induced CCL5 release was attenuated by sulfasalazine (a well-described inhibitor of NF-kappaB activity), BAY 11-7082 (an IkappaB phosphorylation inhibitor), and ALLN (a well-described inhibitor of NF-kappaB activation that prevents degradation of IkappaB and eventually results in a lack of translocated NF-kappaB in the nucleus). In addition, stimulation of TLR2-expressing cells with M. bovis BCG resulted in translocation of NF-kappaB subunits from the cytoplasmic to the nuclear fraction, and stimulation of cells with M. bovis BCG activated IkappaB kinase alphabeta. These findings indicate that M. bovis BCG induces CCL5 production through mechanisms that include a TLR2-dependent component that requires JNK and NF-kappaB activities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17989335      PMCID: PMC2238044          DOI: 10.1128/CVI.00368-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  43 in total

Review 1.  Toll-like receptors in innate immunity.

Authors:  Kiyoshi Takeda; Shizuo Akira
Journal:  Int Immunol       Date:  2005-01       Impact factor: 4.823

2.  Tissue-specific mRNA expression profiles of human toll-like receptors and related genes.

Authors:  Masuhiro Nishimura; Shinsaku Naito
Journal:  Biol Pharm Bull       Date:  2005-05       Impact factor: 2.233

Review 3.  TLR signaling.

Authors:  S Akira
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

Review 4.  Pathogen recognition and innate immunity.

Authors:  Shizuo Akira; Satoshi Uematsu; Osamu Takeuchi
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

Review 5.  Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large.

Authors:  Bruce Beutler; Zhengfan Jiang; Philippe Georgel; Karine Crozat; Ben Croker; Sophie Rutschmann; Xin Du; Kasper Hoebe
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

6.  Production of chemokine CXCL1/KC by okadaic acid through the nuclear factor-kappaB pathway.

Authors:  Gong Feng; Yoshihiro Ohmori; Pi-Ling Chang
Journal:  Carcinogenesis       Date:  2005-07-06       Impact factor: 4.944

7.  Leptospiral membrane proteins stimulate pro-inflammatory chemokines secretion by renal tubule epithelial cells through toll-like receptor 2 and p38 mitogen activated protein kinase.

Authors:  Cheng-Chieh Hung; Chiz-Tzung Chang; Ya-Chung Tian; Mai-Szu Wu; Chun-Chen Yu; Ming-Jeng Pan; Alain Vandewalle; Chih-Wei Yang
Journal:  Nephrol Dial Transplant       Date:  2005-12-08       Impact factor: 5.992

8.  Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes.

Authors:  S A Trushin; K N Pennington; A Algeciras-Schimnich; C V Paya
Journal:  J Biol Chem       Date:  1999-08-13       Impact factor: 5.157

9.  The effect of cyclosporin A on airway cell proinflammatory signaling and pneumonia.

Authors:  Valerie Waters; Sach Sokol; Bharat Reddy; Grace Soong; Jarin Chun; Alice Prince
Journal:  Am J Respir Cell Mol Biol       Date:  2005-05-05       Impact factor: 6.914

10.  A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with increased susceptibility to pulmonary tuberculosis.

Authors:  Pedro O Flores-Villanueva; Jorge A Ruiz-Morales; Chang-Hwa Song; Ludmila M Flores; Eun-Kyeong Jo; Marta Montaño; Peter F Barnes; Moises Selman; Julio Granados
Journal:  J Exp Med       Date:  2005-12-13       Impact factor: 14.307

View more
  4 in total

1.  Mycobacterium bovis bacillus Calmette-Guerin therapy is a potent immunostimulator for management of systemic malignancies.

Authors:  Shailendra Kapoor
Journal:  Clin Vaccine Immunol       Date:  2008-08

2.  Protein kinase Ds promote tumor angiogenesis through mast cell recruitment and expression of angiogenic factors in prostate cancer microenvironment.

Authors:  Wanfu Xu; Jiabi Qian; Fangyin Zeng; Songyu Li; Wenjing Guo; Liping Chen; Guihuan Li; Zhishuai Zhang; Qiming Jane Wang; Fan Deng
Journal:  J Exp Clin Cancer Res       Date:  2019-03-06

3.  Complex cytokine profiles induced by BCG vaccination in UK infants.

Authors:  Maeve K Lalor; Steven G Smith; Sian Floyd; Patricia Gorak-Stolinska; Rosemary E Weir; Rose Blitz; Keith Branson; Paul E Fine; Hazel M Dockrell
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

4.  Biglycan- and Sphingosine Kinase-1 Signaling Crosstalk Regulates the Synthesis of Macrophage Chemoattractants.

Authors:  Louise Tzung-Harn Hsieh; Madalina-Viviana Nastase; Heiko Roedig; Jinyang Zeng-Brouwers; Chiara Poluzzi; Stephanie Schwalm; Christian Fork; Claudia Tredup; Ralf P Brandes; Malgorzata Wygrecka; Andrea Huwiler; Josef Pfeilschifter; Liliana Schaefer
Journal:  Int J Mol Sci       Date:  2017-03-09       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.